SU101 signal transduction inhibitor: SUGN began a Phase I dose escalation trial

SUGEN Inc. (SUGN), Redwood City, Calif. Product: SU101 signal transduction inhibitor Indication: Solid tumors Status: SUGN began a Phase I dose escalation trial using a revised dosing regimen in patie...